118 related articles for article (PubMed ID: 33907111)
21. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
22. Verification and comparison of three prediction models of ischemic stroke in young adults based on the back propagation neural networks.
Chen Y; Mao Y; Pan X; Jin W; Qiu T
Medicine (Baltimore); 2021 Mar; 100(11):e25081. PubMed ID: 33725985
[TBL] [Abstract][Full Text] [Related]
23. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
[TBL] [Abstract][Full Text] [Related]
24. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
Jung K; Stephan C; Lein M; Brux B; Sinha P; Schnorr D; Loening SA
Prostate; 2001 Mar; 46(4):307-10. PubMed ID: 11241553
[TBL] [Abstract][Full Text] [Related]
25. Pre-operative prediction of advanced prostatic cancer using clinical decision support systems: accuracy comparison between support vector machine and artificial neural network.
Kim SY; Moon SK; Jung DC; Hwang SI; Sung CK; Cho JY; Kim SH; Lee J; Lee HJ
Korean J Radiol; 2011; 12(5):588-94. PubMed ID: 21927560
[TBL] [Abstract][Full Text] [Related]
26. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.
Tosoian JJ; Birer SR; Jeffrey Karnes R; Zhang J; Davicioni E; Klein EE; Freedland SJ; Weinmann S; Trock BJ; Dess RT; Zhao SG; Jackson WC; Yamoah K; Dal Pra A; Mahal BA; Morgan TM; Mehra R; Kaffenberger S; Salami SS; Kane C; Pollack A; Den RB; Berlin A; Schaeffer EM; Nguyen PL; Feng FY; Spratt DE
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):646-653. PubMed ID: 32231245
[TBL] [Abstract][Full Text] [Related]
27. Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.
Hill OT; Mason TJ; Schwartz SW; Foulis PR
BMC Urol; 2013 Jan; 13():6. PubMed ID: 23356551
[TBL] [Abstract][Full Text] [Related]
28. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
[TBL] [Abstract][Full Text] [Related]
29. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
30. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study).
Frontini MG; Srinivasan SR; Xu JH; Tang R; Bond MG; Berenson G
Am J Cardiol; 2007 Jul; 100(1):64-8. PubMed ID: 17599442
[TBL] [Abstract][Full Text] [Related]
31. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
32. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy.
Lughezzani G; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Fossati N; Lista G; Larcher A; Abrate A; Mistretta A; Bini V; Palou Redorta J; Graefen M; Guazzoni G
Eur Urol; 2014 Nov; 66(5):906-12. PubMed ID: 24361258
[TBL] [Abstract][Full Text] [Related]
33. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
[TBL] [Abstract][Full Text] [Related]
34. PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population.
Nyberg M; Ulmert D; Lindgren A; Lindström U; Abrahamsson PA; Bjartell A
Scand J Urol Nephrol; 2010 Dec; 44(6):378-83. PubMed ID: 20961267
[TBL] [Abstract][Full Text] [Related]
35. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
36. The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance but not of β cell function in a Chinese population with different glucose tolerance status.
Zhou M; Zhu L; Cui X; Feng L; Zhao X; He S; Ping F; Li W; Li Y
Lipids Health Dis; 2016 Jun; 15():104. PubMed ID: 27267043
[TBL] [Abstract][Full Text] [Related]
37. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
38. Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.
Boehm K; Larcher A; Beyer B; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Heinzer H; Graefen M; Budäus L
Eur Urol; 2016 Jun; 69(6):1038-43. PubMed ID: 26272236
[TBL] [Abstract][Full Text] [Related]
39. Comparison of lipoprotein derived indices for evaluating cardio-metabolic risk factors and subclinical organ damage in middle-aged Chinese adults.
Cao X; Wang D; Zhou J; Chen Z
Clin Chim Acta; 2017 Dec; 475():22-27. PubMed ID: 28969987
[TBL] [Abstract][Full Text] [Related]
40. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.
van der Steeg WA; Boekholdt SM; Stein EA; El-Harchaoui K; Stroes ES; Sandhu MS; Wareham NJ; Jukema JW; Luben R; Zwinderman AH; Kastelein JJ; Khaw KT
Ann Intern Med; 2007 May; 146(9):640-8. PubMed ID: 17470832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
